Levothyroxine NDAs May Be Refused Filing After First Product Approval - FDA
Executive Summary
Levothyroxine NDAs may be refused filing following approval of the first levothyroxine product, FDA said in a draft guidance issued August 18.
You may also be interested in...
Abbott Synthroid NDA To Include Clinical Study Data; Citizen Petition Rejected
Abbott will file data from clinical studies, including bioavailability and pharmacokinetic data, to support its NDA for the thyroid agent Synthroid.
Abbott Synthroid NDA To Include Clinical Study Data; Citizen Petition Rejected
Abbott will file data from clinical studies, including bioavailability and pharmacokinetic data, to support its NDA for the thyroid agent Synthroid.
Glaxo To File ANDA For Lanoxin Elixir, Requests Two-Years For Approval
GlaxoSmithKline plans to file an ANDA for Lanoxin Elixir using the tablet formulation of its cardiac drug Lanoxin (digoxin) as its reference drug.